Edwards Lifesciences to announce Q2 results on July 23

0 min read Updated on 16 Jul 2026, 05:18 PM

Reviewed by

Naman SScanX News Team

AI Summary

Edwards Lifesciences will release Q2 2026 results on July 23, followed by a conference call at 5:00 p.m. ET. Investors can join via phone or webcast.

*this image is generated using AI for illustrative purposes only.

Edwards Lifesciences will announce its operating results for the quarter ended June 30, 2026, after the market closes on July 23. The company will host a conference call at 5:00 p.m. ET on the same day to discuss the financial performance.

Conference Call Details

Investors can participate in the conference call by dialing (877) 704-2848 or (201) 389-0893. The call will also be accessible live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com.

About Edwards Lifesciences

Edwards Lifesciences is a global structural heart innovation company focused on improving patient lives through breakthrough technologies and partnerships with clinicians. The company's products and solutions are designed to address unmet medical needs in the structural heart disease space.

What are the key performance indicators investors should focus on during the Q2 2026 earnings call?

How might Edwards Lifesciences' recent innovations impact its financial results for the quarter?

What competitive pressures could affect Edwards Lifesciences' market position in the structural heart disease space?

Read Next Article

Mizuho raises Edwards Lifesciences target to $105

1 min read Updated on 16 Jul 2026, 02:36 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

AI Summary

Mizuho analyst Anthony Petrone maintained an Outperform rating on Edwards Lifesciences, raising the price target to $105 from $100. This follows similar upward revisions by RBC Capital, BTIG, Evercore ISI Group, and Citigroup.

*this image is generated using AI for illustrative purposes only.

Edwards Lifesciences (NYSE: EW) has received a raised price target from Mizuho, adding to a series of bullish revisions from multiple analysts. The adjustments reflect growing confidence in the medical device company's valuation potential and market positioning.

Mizuho analyst Anthony Petrone maintained an Outperform rating and increased the price target to $105 from $100. This aligns with similar upward adjustments from other firms. RBC Capital analyst Shagun Singh maintained an Outperform rating and increased the price target to $110 from $100. BTIG analyst Marie Thibault maintained a Buy rating and raised the price target to $110 from $100. Evercore ISI Group analyst Vijay Kumar kept an Outperform rating and lifted the price target to $100, up from $93. Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $101 to $110.

Analyst Ratings and Price Targets

The revised targets from all five firms underscore optimism for the company's stock trajectory.

Firm	Analyst	Rating	Previous Target	New Target
Mizuho	Anthony Petrone	Outperform	$100	$105
RBC Capital	Shagun Singh	Outperform	$100	$110
BTIG	Marie Thibault	Buy	$100	$110
Evercore ISI Group	Vijay Kumar	Outperform	$93	$100
Citigroup	Joanne Wuensch	Buy	$101	$110